More about the combination of rituximab, cyclosporine and dexamethasone in the treatment of chronic ITP. A useful option on an environment with limited resources
Treatment of chronic primary immune thrombocytopenia (ITP) is challenging especially with limited resources and therapy-related complications. This prospective interventional study assessed the efficacy and safety of triple therapy(TT4); a combination treatment of oral dexamethasone 40 mg for days1-...
Main Authors: | Ahmad F. Thabet, Sawsan M. Moeen |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-08-01
|
Series: | Platelets |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09537104.2019.1678121 |
Similar Items
-
Lifting the fog over ITP
by: Philip Young-Ill Choi
Published: (2020-04-01) -
Rituximab resistance in ITP and beyond
by: Zhengrui Xiao, et al.
Published: (2023-07-01) -
Learning the Ropes of Platelet Count Regulation: Inherited Thrombocytopenias
by: Loredana Bury, et al.
Published: (2021-02-01) -
Selective serotonin reuptake inhibitors related bleeding risk: case report and review of literature
by: Andrea Boccatonda, et al.
Published: (2023-08-01) -
Novel scientific approaches and future research directions in understanding ITP
by: Sarah M. Hicks, et al.
Published: (2020-04-01)